Mathias brings world-class innovation and contract development and manufacturing experience to Oxford Biomedica. Since 2016, he has been CEO of Rentschler Biopharma SE, which has successfully developed into a world-leading full-service CDMO. Over the past six years, Mathias has tripled his revenue growth, transforming the business, increasing efficiency and increasing profitability faster than revenue. At Rentschler, he also led the acquisition and rapid integration of a new facility from Shire in Milford, near Boston, USA, and the establishment of a new gene therapy unit in Stevenage, UK. During his tenure, Rentschler was also the first of his CDMOs in Europe to support the commercial production of BioNTech’s mRNA vaccines, and also successfully transferred the commercial production process of Curevac’s mRNA vaccines.
Prior to Rentschler, Matthias was CEO of publicly traded Medigene AG, an immuno-oncology company focused on developing T-cell-based cancer therapies. During his 30-year career, Matthias has also held senior positions at leading global pharmaceutical companies such as Amgen, Servier and Hoechst AG. In 2019 he was awarded the title of ‘EY Entrepreneur of the Year’ in Germany.
Dr. Roch Doliveux will remain as interim CEO of Oxford Biomedica until March 2023, at which time Mathias will assume the full CEO role and Doliveux will resume his non-executive chair role.
Commenting on this appointment, Doliveux said: Frank is an accomplished patient-focused leader with impressive experience in his top-end CDMOs and innovative biopharmaceutical companies. He has a strong track record of delivering growth and driving performance and innovation. This is the core strength we need to execute our strategy of becoming an innovative viral vector leader. I know Frank will drive leadership in viral vectors and biopharmaceutical companies unlocking the potential of cell and gene therapy to save many lives. “
Mathias commented: I am excited about the company’s potential as it continues to gain momentum across the business. To join Oxford Biomedica and work with all staff, boards and partners to execute strategy and deliver the next phase of growth as his CDMO, a world-class innovation-driven company that improves patient lives. looking forward to ”